Form 8-K - Current report:
SEC Accession No. 0001683168-25-000426
Filing Date
2025-01-17
Accepted
2025-01-17 16:05:09
Documents
19
Period of Report
2025-01-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT phio_8k.htm   iXBRL 8-K 39543
2 FORM OF SERIES I COMMON STOCK WARRANT, DATED JANUARY 17, 2025 phio_ex0401.htm EX-4.1 114689
3 FORM OF PLACEMENT AGENT WARRANT, DATED JANUARY 17, 2025 phio_ex0402.htm EX-4.2 116063
4 OPINION OF HOGAN LOVELLS US LLP phio_ex0501.htm EX-5.1 8972
5 FORM OF SECURITIES PURCHASE AGREEMENT, DATED JANUARY 16, 2025 phio_ex1001.htm EX-10.1 270717
6 PRESS RELEASE ISSUED BY THE COMPANY ON JANUARY 16, 2025 phio_ex9901.htm EX-99.1 13411
10 GRAPHIC image_002.jpg GRAPHIC 3077
  Complete submission text file 0001683168-25-000426.txt   871249

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE phio-20250116.xsd EX-101.SCH 3021
8 XBRL LABEL FILE phio-20250116_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE phio-20250116_pre.xml EX-101.PRE 22363
21 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 25538660
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)